Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | How patients are involved in treatment decisions following a genomic test

Michel van Gelder • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

Michel van Gelder, MD, PhD, Maastricht University, Maastricht, Netherlands, shares some insights into how patients with chronic lymphocytic leukemia (CLL) are involved in treatment decision-making following a genomic test, highlighting the availability of various therapeutic options in The Netherlands, including chemoimmunotherapy (CIT) and novel agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michel van Gelder

1:37
The importance of genomic testing in the diagnosis of CLL
Michel van Gelder • 7 Oct 2022
3:51
The role of frontline chemoimmunotherapy in the era of novel agents in CLL
Michel van Gelder • 7 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals